News
Secure
Monday 06 Sep 10
Insights into the role of progesterone receptors in
breast cancer.
Fuqua,
S. A. W., Cui, Y. K., Lee, A. V., Osborne, C. K., Horwitz, K. B., Olivotto, I.
A., Vernstein, V., and Truong, P. T.
Journal of Clinical Oncology 23(4),
931-2, 932, 933. 2005.
Aromatase
inhibition: Translation into a successful therapeutic approach.
Geisler, J. and Lonning, P. E.
Clinical Cancer Research 11(8), 2809-2821.
2005.
Aromatase
inhibitors in advanced breast cancer: there are efficacy differences.
Bhatnagar, A. S. and Sainsbury, R.
British Journal of Cancer 92(6),
1173-4, 1174, 1175, 1176. 2005.
Aromatase
inhibitor agents in breast cancer: Evolving practices in hormonal therapy
treatment.
Viale,
P. H.
Oncology
Nursing Forum 32(2), 343-351. 2005.
Skeletal health in postmenopausal survivors of early
breast cancer.
Mackey, J. R. and Joy, A. A.
International
Journal of Cancer 114(6), 1010-1015. 2005.
Aromatase inhibitors and bone.
Eastell,
R.
Cancer Treatment Reviews 31(Suppl 1), S21-S22. 2005.
The emerging role of the new aromatase inhibitors in
the treatment of breast cancer.
Sulkes, A.
Prevention in breast cancer.
Untch,
M.
Arzneimittel Forschung 55(3), 187-188. 2005.
Hormone
therapy in breast cancer: the end of tamoxifen?
Delozier,
T.
Bulletin du Cancer 92(2), 142-150.
2005.
Evolving
treatment approaches for early breast cancer.
Breast Cancer Research and Treatment 89(Suppl 1),
S1-S7. 2005.
Anastrozole, the new standard in early breast
carcinoma.
Queisser,
Luft A.
Gynakologe 38(1), A1-15.
2005.
Thrombotic complications and thromboprophylaxis in
breast and gynaecological malignancies.
Goyal, D., Choudhury, A., and Lip, G. Y. H.
Current
Opinion in Obstetrics and Gynecology 17(1), 13-20. 2005.
Advances in adjuvant hormonal therapy for
postmenopausal women.
Strasser, Weippl K. and Goss, P. E.
Journal of Clinical Oncology 23(8), 1751-1759. 2005.
Aromatase inhibitors for breast cancer prevention.
Cuzick,
J.
Journal of Clinical Oncology 23(8), 1636-1643. 2005.
Aromatase
inhibitors: Rationale and use in breast cancer .
Osborne, C. and Tripathy, D.
Annual
Review of Medicine 56 Pages, 103-116. 2005.
Breast
cancer therapy: Anastrozole and fulvestrant broaden the choice of treatment.
Geburtshilfe und Frauenheilkunde
65(1), A1-A4. 2005.
Aromatase inhibitors in the treatment of early and
advanced breast cancer.
Joensuu, H., Ejlertsen, B., Lonning, P. E., and
Rutqvist, L. E.
Acta
Oncologica 44(1), 23-31. 2005.
Endocrine
responsiveness: Understanding how progesterone receptor can be used to select
endocrine therapy.
Osborne,
K.
Breast 14(Suppl 1), S5.
2005.
Prevention
of breast cancer: Whats new.
Cuzick,
J.
Breast 14(Suppl 1), S3.
2005.
The choice of systemic adjuvant therapy in
receptor-positive early breast cancer.
Dellapasqua, S. and Castiglione, Gertsch M.
European
Journal of Cancer 41(3), 357-364. 2005.
How
rapidly do oncologists respond to clinical trial data?
Buzdar,
A. and Macahilig, C.
Oncologist
10(1), 15-21. 2005.
Tamoxifen versus aromatase inhibitors for breast
cancer prevention.
Yue,
W., Wang, J. P., Li, Y. B., Bocchinfuso, W. P., Korach, K. S., Devanesan, P.
D., Rogan, E., Cavalieri, E., and Santen, R. J.
Clinical
Cancer Research 11(2 Pt 2 Supplement), 925S-930S. 2005.
Safety
and tolerability data from the
Distler,
W.
Breast 14(Suppl 1), Abs. 2005.
Proceedings
of the Fourth International Conference on Recent Advances and Future Directions
in Endocrine Manipulation of Breast Cancer: Conference summary statement.
Come,
S. E., Buzdar, A. U., Ingle, J. N., Arteaga, C. L., Brodie, A. M., Colditz, G.
A., Johnston, S. R. D., Kristensen, V. N., Lonning, P. E., McDonnell, D. P.,
Osborne, C. K., Russo, J., Santen, R. J., Yee, D., and Hart, C. S.
Clinical
Cancer Research 11(2 II Supplement), 861s-864s. 2005.
Endocrine
therapy trials of aromatase inhibitors for breast cancer in the adjuvant and
prevention settings.
Ingle,
J. N., Johnston, S., Osborne, K., Come, S., Lonning, P., Santen, R., and
Buzdar, A.
Clinical
Cancer Research 11(2 II Supplement), 900s-905s. 2005.
Exemestane
for breast cancer prevention: A feasible strategy?
Lonning,
P. E., Buzdar, A., Santen, R., Johnston, S., Arteaga, C., and Yee, D.
Clinical
Cancer Research 11(2 II Supplement), 918s-924s. 2005.
Short-term
changes in Ki-67 during neoadjuvant treatment of primary breast cancer with
anastrozole or tamoxifen alone or combined correlate with recurrence-free
survival.
Dowsett,
M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C.,
Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., Francis, S.,
Walsh, G., Santen, R., Johnston, S., Lonning, P., Russo, J., and Ingle, J.
Clinical
Cancer Research 11(2 II Supplement), 951s-958s. 2005.
Prevention
of hormone-related cancers: Breast cancer.
Dunn,
B. K., Wickerham, D. L., and Ford, L. G.
Journal
of Clinical Oncology 23(2), 357-367. 2005.
Endocrine
treatment options for advanced breast cancer - the role of fulvestrant.
Robertson,
J. F. R., Come, S. E., Jones, S. E., Beex, L., Kaufmann, M., Makris, A.,
Nortier, J. W. R., Possinger, K., and Rutqvist, L. E.
European
Journal of Cancer 41(3), 346-356. 2005.
The
Duffy,
S., Jackson, T. L., Lansdown, M., Philips, K., Wells, M., Pollard, S., Clack,
G., Coibion, M., and Bianco, A. R.
Human
Reproduction 20(1), 294-301. 2005.
Aromatase
inhibitors and mental function.
Tralongo,
P., Dimari, A., and Repetto, L.
Journal of the American Geriatrics Society 53(1), 166.
2005.
Results
of the
Lancet
365(9453), 60-62. 2005.
American
society of clinical oncology technology assessment on the use of aromatase
inhibitors as adjuvant therapy for postmenopausal women with hormone
receptor-positive breast cancer: Status report 2004.
Winer,
E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N.,
Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., Cohleigh, M. A.,
Mamounas, E. P., Goldstein, L. J., Whelan, T. J., Powles, T. J., Bryant, J.,
Perkins, C., Perotti, J., Braun, S., Langer, A. S., Browman, G. P., and
Somerfield, M. R.
Journal
of Clinical Oncology 23(3), 619-629. 2005.
Significance
of osteoporosis after chemotherapy in breast cancer.
Friedrich,
M., Diesing, D., and Diedrich, K.
Gynakologe
37(Suppl 1), S32-S37. 2004.
Cost-utility
analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal
women with early breast cancer from a US healthcare perspective. The
Locker,
G. Y.
Breast Cancer Research and Treatment 88(Suppl 1),
S105, Abs. 2004.
The
Howell,
A.
Breast Cancer Research and Treatment 88(Suppl 1), S7,
Abs. 2004.
Audit
of adjuvant endocrine therapy in the UK.
Doughty,
J. C., Horgan, K., Wilson, C. R., and Bishop, H.
Breast Cancer Research and Treatment 88(Suppl 1),
S239, Abs. 2004.
Tamoxifen
and aromatase inhibitors in the treatment of breast cancer in menopausal women:
pharmacological and clinical aspects.
De
Cremoux, P., Diéras, W., Poupon, M. F., Magdelénat, H., Sigal, Zafrani B.,
Fourquet, A., and Pierga, J. Y.
Bulletin
du Cancer 91(12), 917-927. 2004.
Clinical
prevention of breast and prostate cancers.
Greenwald,
P.
Cancer Epidemiology Biomarkers and Prevention 13(11 Pt
2), 1953S. 2004.
Cognitive
function a longitudinal study of the effects of anastrozole on cognition in
post-menopausal women at risk of developing breast cancer.
Atkins,
L., Jenkins, V., Fallowfield, L. J., and Howell, A.
Psycho Oncology 13(8 Supplement), S21, Abs. 2004.
Aromatase
inhibitors in adjuvant setting in breast cancer.
Spano,
J. P., Khayat, D., and Delozier, T.
Bulletin
du Cancer 91 Pages, S239-S243. 2004.
European
school of oncology Advanced Course on Cancer in the Elderly Liverpool, 29-30
April 2004.
Bruce,
C., Osman, N., Audisio, R. A., and Aapro, M. S.
Surgical
Oncology 13(4), 159-167. 2004.
Aromatase
inhibitors and breast cancer: Time for a change?
Fentiman,
I. S.
International
Journal of Clinical Practice 58(12), 1152-1158. 2004.
Growth
factor-driven mechanisms associated with resistance to estrogen deprivation in
breast cancer: new opportunities for therapy.
Nicholson,
R. I., Staka, C., Boyns, F., Hutcheson, I. R., and Gee, J. M. W.
Endocrine
Related Cancer 11(4), 623-641. 2004.
Evaluation
of the impact of estrogen receptor (ER) and progesterone receptor (PgR) status
on time to recurrence in the ATAC (‘Arimidex’, Tamoxifen, Alone or in
Combination) trial.
Dowsett,
M.
Proceedings
of the 28th Annual Symposium of the American Society of Breast Disease . 2004.
Aromatase
inhibitors in early breast cancer therapy.
Smith,
I. E.
Seminars
in Oncology 31(6 Supplement), 9-14. 2004.
Aromatase
inhibitors in the management of early breast cancer: Optimizing the clinical
benefit.
Henderson,
I. C.
Seminars
in Oncology 31(6 Supplement), 31-34. 2004.
Correlation
of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx
and ERbeta5 with outcome in endocrine-treated breast cancer.
Davies,
M. P. A., O'Neill, P. A., Innes, H., Sibson, D. R., Prime, W., Holcombe, C.,
and Foster, C. S.
Journal
of Molecular Endocrinology 33(3), 773-782. 2004.
Are
all aromatase inhibitors the same? - A review of the current evidence.
Jänicke,
F.
Breast
13(Suppl 1), S10-S18. 2004.
Long-term
implications of bone loss in breast cancer.
Aapro,
M. S.
Breast
13(Suppl 1), S29-S37. 2004.
Molecular
markers in the endometrium at baseline of postmenopausal patients with early
breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Duffy,
S. R. G. and Taylor, L.
American
Journal of Obstetrics and Gynecology 191(6), 1921-1927. 2004.
E9.
Side-effects of tamoxifen and solutions with aromatase inhibitors.
Cuzick,
J.
European Journal Of Cancer Supplements 2(9 SPEC. ISS),
33-34. 2004.
E12.
Predictors of resistance to hormonal therapy in breast cancer.
Dowsett,
M., Martin, L. A., Johnston, S., and Smith, I. E.
European Journal Of Cancer Supplements 2(9 SPEC. ISS),
43-44. 2004.
E17.
Are aromatase inhibitors superior to tamoxifen after the menopause.
Buzdar,
A. U.
European Journal Of Cancer Supplements 2(9 SPEC. ISS),
54-55. 2004.
E20.
Neoadjuvant endocrine therapy in breast cancer.
Dixon,
J. M.
European Journal Of Cancer Supplements 2(9 SPEC. ISS),
60-61. 2004.
E21.
What is the best therapy for ER-positive breast cancer?
Klijn,
J. G. M.
European Journal Of Cancer Supplements 2(9 SPEC. ISS),
62-64. 2004.
Time
for a change in breast cancer therapy?
Cameron,
D.
Hospital
Medicine 65(12), 724-729. 2004.
Biomarker
investigations from the ATAC trial: the role of TA01.
Dowsett,
M., Ellis, I., Allred, C., Paik, S., Bishop, H., Diver, J., Houghton, J.,
Howell, T., Larsimont, D., Mallon, E., Sapunar, F., Sasano, H., and Williams,
N.
Breast
Cancer Research and Treatment 87(Suppl 1), S11-S18. 2004.
Designing
the future shape of breast cancer diagnosis, prognosis and treatment.
Dowsett,
M.
Breast
Cancer Research and Treatment 87(Suppl 1), S27-S29. 2004.
Translational
research and the changing face of breast cancer.
Dowsett,
M.
Breast
Cancer Research and Treatment 87(Suppl 1), S1-S2. 2004.
Recent
advances in endocrine therapy for postmenopausal women with early breast
cancer: implications for treatment and prevention.
Tobias,
J. S.
Annals
of Oncology 15(12), 1738-1747. 2004.
ATAC
(‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis:
Anastrozole demonstrates superior efficacy and tolerability compared with
tamoxifen.
Howell,
A. and ATAC Trialists' Group
Breast
Cancer Research and Treatment 88(suppl 1), S7, Abs. 2004.
Cost-utility
analysis of anastrozole versus tamoxifen as primary adjuvant therapy in
postmenopausal women with early breast cancer from a US healthcare system
perspective: the 5-year completed treatment analysis of the ATAC (‘Arimidex’,
Tamoxifen Alone or in Combination) trial.
Locker,
G. Y.
Breast
Cancer Research and Treatment 88(Suppl 1), S105, Abs. 2004.
Controversies
in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment
strategies.
D'Hondt,
V. and Piccart, M.
Annals
of Oncology 15(Suppl 4), 23-29. 2004.
Fulvestrant
- A new type of estrogen receptor antagonist for the treatment of advanced
breast cancer.
Buzdar,
A. U.
Drugs
of Today 40(9), 751-764. 2004.
Should
tamoxifen be used in breast cancer prevention?
Kramer,
R. and Brown, P.
Drug
Safety 27(13), 979-989. 2004.
Effects
of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac,
D., Macedo, L., Handratta, V., Long, B. J., Goloubeva, O. G., Ingle, J. N., and
Brodie, A. M. H.
Clinical
Cancer Research 10(21), 7375-7381. 2004.
Quality
of life of postmenopausal women in the arimidex, tamoxifen, alone or in
combination (ATAC) adjuvant breast cancer trial.
Fallowfield,
L., Cella, D., Cuzick, J., Francis, S., Locker, G., and Howell, A.
Journal
of Clinical Oncology 22(21), 4261-4271. 2004.
Managing
early breast cancer - Prognostic features guide choice of therapy.
Mirshahidi,
H. R. and Abraham, J.
Postgraduate
Medicine 116(4), 23-6, 32. 2004.
Future
options with trastuzumab for primary systemic and adjuvant therapy.
Baselga,
J., Gianni, L., Geyer, C., Perez, E. A., Riva, A., and Jackisch, C.
Seminars
in Oncology 31(5 Supplement), 51-57. 2004.
Perspectives
on the future of bisphosphonate use in breast cancer patients.
Clemons,
M. and Rea, D.
Seminars
in Oncology 31(5 Supplement), 87-91. 2004.
Accelerated
approval of oncology products: A decade of experience.
Dagher,
R., Johnson, J., Williams, G., Keegan, P., and Pazdur, R.
Journal
of the National Cancer Institute 96(20), 1500-1509. 2004.
Risk
of ischemic stroke with tamoxifen treatment for breast cancer - A meta-analysis.
Bushnell,
C. D. and Goldstein, L. B.
Neurology
63(7), 1230-1233. 2004.
The
role of aromatase inhibitors on the adjuvant treatment of breast carcinoma -
The M. D. Anderson Cancer Center evidence-based approach.
Morandi,
P., Rouzier, R., Altundag, K., Buzdar, A. U., Theriault, R. L., and Hortobagyi,
G.
Cancer
101(7), 1482-1489. 2004.
Role
of aromatase inhibitors in the treatment of breast cancer.
Choueiri,
T. K., Alemany, C. A., Abou Jawde, R. M., and Budd, G. T.
Clinical
Therapeutics 26(8), 1199-1214. 2004.
Advances
in adjuvant therapy for breast cancer.
Smith,
I.
Clinical Oncology 16(6), S11-2, Abs. 2004.
Developments
in breast cancer during 2003-2004.
Makris,
A.
Clinical Oncology 16(6), S16, Abs. 2004.
Exemestane
following tamoxifen in postmenopausal women with primary breast cancer.
Mouridsen,
H. T.
Journal of Clinical Oncology 22(18), 3833-3834. 2004.
Endocrine
approaches for the treatment of early and advanced breast cancer in
postmenopausal women.
Tobias,
J. S.
International
Journal of Biochemistry & Cell Biology 36(11), 2112-2119. 2004.
Switching
to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free
survival, but not overall survival, in postmenopausal women surviving primary
breast cancer, compared with continuous tamoxifen.
Davies,
C.
Cancer Treatment Reviews 30(6), 583-588. 2004.
Breast
radiotherapy after lumpectomy - No longer always necessary.
Smith,
I. E. and Ross, G. M.
New England Journal of Medicine 351(10), 1021-1023.
2004.
Aromatase
inhibitors: Possible future applications.
Karaer,
O., Oruc, S., and Koyuncu, F. M.
Acta
Obstetricia et Gynecologica Scandinavica 83(8), 699-706. 2004.
Tamoxifen
- What next?
Gradishar,
W. J.
Oncologist
9(4), 378-384. 2004.
Breast
surgery in the 'Arimidex, tamoxifen alone or in combination' (ATAC) trial -
American women are more likely than women from the United Kingdom to undergo
mastectomy.
Locker,
G. Y., Sainsbury, J. R., and Cuzick, J.
Cancer
101(4), 735-740. 2004.
Breast
cancer chemoprevention: quo vadis?
Powles,
T.
European Journal Of Cancer Supplements 2(1), 20, Abs.
2004.
The
risk of venous thromboembolic disease associated with adjuvant hormone therapy
for breast carcinoma: A systematic review.
Deitcher,
S. R. and Gomes, M. P. V.
Cancer
101(3), 439-449. 2004.
Impact
of prior chemotherapy regimens on the relative efficacy of endocrine therapy:
an exploratory analysis of data from the ATAC (‘Arimidex’, Tamoxifen, Alone or
in Combination) trial on behalf of the ATAC Trialists’ Group.
Buzdar, A. and Nabholtz, J.-M. 2004.
Summary:
Aromatase inhibitors in the adjuvant therapy of breast cancer.
Baumann,
C. K. and Aebi, S.
Therapeutische
Umschau 61(6), 359-364. 2004.
The
role of COX-2 inhibition in breast cancer treatment and prevention.
Arun,
B. and Goss, P.
Seminars in Oncology 31(2 Supplement), 22-29. 2004.
Overcoming
endocrine therapy resistance by signal transduction inhibition.
Ellis,
M.
Oncologist
9(Suppl 3), 20-26. 2004.
An
economic evaluation of anastrozole versus tamoxifen as adjuvant therapy in
postmenopausal women with early breast cancer (EBC) from a US healthcare
perspective.
Locker,
G. Y.
Program/proceedings
- American Society of Clinical Oncology 23 Pages, 24, Abs. 2004.
Advances
in screening, diagnosis, and treatment of breast cancer.
Mincey,
B. A. and Perez, E. A.
Mayo
Clinic Proceedings 79(6), 810-816. 2004.
Pharmacogenetics
in the treatment of breast cancer.
Stearns,
V., Davidson, N. E., and Flockhart, D. A.
Pharmacogenomics Journal 4(3), 143-153. 2004.
What
is the effect of systemic anticancer treatment on cognitive function?
Minisini,
A., Atalay, G., Bottomley, A., Puglisi, F., Piccart, M., and Biganzoli, L.
Lancet
Oncology 5(5), 273-282. 2004.
New
concepts in breast cancer therapy.
Snyder,
R. D.
Internal
Medicine Journal 34(5), 266-269. 2004.
Anastrozole
is safer and may be more effective than tamoxifen in postmenopausal women with
early-stage breast cancer.
Carraway,
H. and Wolff, A. C.
Cancer Treatment Reviews 30(3), 303-307. 2004.
Aromatase
inhibitors: New endocrine treatment of breast cancer.
Brueggemeier,
R. W.
Seminars
In Reproductive Medicine 22(1), 31-43. 2004.
Targeting
oestrogen to kill the cancer but not the patient.
Lewis,
J. S., Cheng, D., and Jordan, V. C.
British
Journal of Cancer 90(5), 944-949. 2004.
Guidelines
for the management of women at increased familial risk of breast cancer.
Sauven,
P.
European
Journal of Cancer 40(5), 653-665. 2004.
Therapeutic
strategies using the aromatase inhibitor letrozole and tamoxifen in a breast
cancer model.
Long,
B. J., Jelovac, D., Handratta, V., Thiantanawat, A., Macpherson, N., Ragaz, J.,
Goloubeva, O. G., and Brodie, A. M.
Journal
of the National Cancer Institute 96(6), 456-465. 2004.
Pharmacoeconomic
aspects of adjuvant early breast cancer treatment in postmenopausal women with
anastrozole or tamoxifen: a Slovenian perspective.
Piskur,
P., Sonc, M., Cufer, T., Borstnar, S., and Mrhar, A.
European Journal Of Cancer Supplements 2(3), 75, Abs.
2004.
Cost-effectiveness
of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with
early breast cancer: a UK National Health Service perspective.
Mansel,
R. E.
European Journal Of Cancer Supplements 2(3), 72, Abs.
2004.
Endocrine
prevention of breast cancer.
Ingle,
J. N.
European Journal Of Cancer Supplements 2(3), 155, Abs.
2004.
Anastrozole
has a protective effect on the endometrium: data from the ATAC ('Arimidex'',
tamoxifen, alone or in combination) trial.
Duffy,
S. and Greenwood, M.
European Journal Of Cancer Supplements 2(3), 140, Abs.
2004.
Molecular
basis of endocrine therapy.
Dowsett,
M.
European Journal Of Cancer Supplements 2(3), 12, Abs.
2004.
Effect
of anastrozole on bone mineral density and bone fractures: results from the
'Arimidex'' (anastrozole), tamoxifen, alone or in combination (ATAC) trial.
Coleman,
R.
European Journal Of Cancer Supplements 2(3), 140, Abs.
2004.
Update
on systemic adjuvant treatment.
Castiglione,
Gertsch M.
European Journal Of Cancer Supplements 2(3), 20, Abs.
2004.
Toward
optimal health: The experts discuss advances in breast cancer management.
Godfrey,
J.
Journal Of Womens Health 13(1), 25-31. 2004.
Progress
in chemoprevention of breast cancer.
Serrano,
D., Perego, E., Costa, A., and Decensi, A.
Critical
Reviews in Oncology/Hematology 49(2), 109-117. 2004.
Fulvestrant:
an oestrogen receptor antagonist with a novel mechanism of action.
Osborne,
C. K., Wakeling, A., and Nicholson, R. I.
British
Journal of Cancer Supplement 90(1), s2-s6. 2004.
Anastrozole
of global value in early breast cancer?
Hunt,
L.
Inpharma
(1422), 5-6. 2004.
Breast
cancer chemoprevention: Quo Vadis?
Powles,
T.
European Journal Of Cancer Supplements 2(1), 20, Abs.
2004.
ATAC
('Arimidex', Tamoxifen, Alone and in Combination) trial: updated results
confirm anastrozole maintains efficacy and tolerability benefits.
Buzdar,
A. U.
/ . 2004.
Advances
in hormonal therapy for breast cancer.
Buzdar, A. U. 2004.
Sequencing
of endocrine therapy in postmenopausal women with advanced breast cancer.
Ingle,
J. N.
Clinical
Cancer Research 10(1 Pt 2 Supplement), 362S-367S. 2004.
Prevention
strategies with aromatase inhibitors.
Goss,
P. E. and Strasser, Weippl K.
Clinical
Cancer Research 10(1 Pt 2 Supplement), 372S-379S. 2004.
Neoadjuvant
endocrine therapy as a drug development strategy.
Ellis,
M. J.
Clinical
Cancer Research 10(1 Pt 2 Supplement), 391S-395S. 2004.
Does
hormone therapy for the treatment of breast cancer have a detrimental effect on
memory and cognition? A pilot study.
Jenkins,
V., Shilling, V., Fallowfield, L., Howell, A., and Hutton, S.
Psycho
Oncology 13(1), 61-66. 2004.
Medical
oncology.
Aapro,
M. S.
Medecine
et Hygiene 62(2464), 19, 21-4, 26. 2004.
Adjuvant
endocrine therapy.
Rutqvist,
L. E.
Bailliere's
Best Practice & Research Clinical Endocrinology & Metabolism 18(1),
81-95. 2004.
Biological
rationale for endocrine therapy in breast cancer.
Miller,
W. R.
Bailliere's
Best Practice & Research Clinical Endocrinology & Metabolism 18(1),
1-32. 2004.
Oestrogen
suppression - lessons from clinical studies.
Lonning,
P. E.
Bailliere's
Best Practice & Research Clinical Endocrinology & Metabolism 18(1),
33-45. 2004.
Aromatase
inhibitors for chemoprevention.
Goss,
P. E. and Strasser, Weippl K.
Bailliere's
Best Practice & Research Clinical Endocrinology & Metabolism 18(1),
113-130. 2004.
Importance
of correlative science in advancing hormonal therapy and a new clinical
paradigm for neoadjuvant therapy.
Ellis,
M. J.
Annals
of Surgical Oncology 11(1 Supplement), 9S-17S. 2004.
Breast-conserving
therapy (BCT) for early-stage breast cancer.
Benda,
R. K., Mendenhall, N. P., Lind, D. S., Cendan, J. C., Shea, B. F., Richardson,
L. C., and Copeland, E. M. I. I.
Journal
of Surgical Oncology 85(1), 14-27. 2004.
Proceedings
of the Third International Conference on Recent Advances and Future Directions
in Endocrine Manipulation of Breast Cancer: Conference summary statement.
Come,
S. E., Buzdar, A. U., Arteaga, C. L., Bissell, M. J., Brown, M. A., Ellis, M.
J., Goss, P. E., Green, J. E., Ingle, J. N., Lee, A. V., Medina, D., Nicholson,
R. I., Santen, R. J., Schiff, R., and Hart, C. S.
Clinical Cancer Research 10(1 Pt 2 Supplement),
327S-330S. 2004.
Data
from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial.
Buzdar,
A. U.
Clinical
Cancer Research 10 Pages, 355S-361S. 2004.
First-line
endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
Wong,
Z. W. and Ellis, M. J.
British
Journal of Cancer 90(1), 20-25. 2004.
The
relationship between aromatase in primary breast tumors and response to
treatment with aromatase inhibitors in advanced disease.
de
Jona, P. C., Blankenstein, M. A., Nortier, J. W. R., Slee, P. H. T. J., Van, De,
V, van Gorp, J. M. H. H., Elbers, J. R. J., Schipper, M. E. I., Blijham, G. H.,
Thijssen, J. H. H., Lu, Q., Jelovac, D., and Brodie, A. M.
Journal
of Steroid Biochemistry and Molecular Biology 87(2-3), 149-155. 2003.
Perspectives
in oncology.
Jänicke,
F.
Onkologie 26(Suppl 7), 3. 2003.
The
ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial
subprotocol data.
Duffy,
S., Jackson, T. L., Lansdown, M., Philips, K., Wells, M., Pollard, S., Clack,
G., Cuzick, J., Coibion, M., and Bianco, A. R.
Bjog:
An International Journal Of Obstetrics & Gynaecology 110(12), 1099-1106.
2003.
Osteopenia
and osteoporosis in women with breast cancer.
Ramaswamy,
B. and Shapiro, C. L.
Seminars
in Oncology 30(6), 763-775. 2003.
Empowering
women with breast cancer: One survivor's story.
Paskett,
E. D.
Seminars in Oncology 30(6), 814-816. 2003.
Pharmacological
prevention of breast cancer: Quo vadis?
Serrano,
D., Bonanni, B., Cazzaniga, M., Galli, A., Gonzaga, A. G., and Decensi, A.
Breast
12(6), 379-386. 2003.
Comments
on the St. Gallen consensus 2003 on the primary therapy of early breast cancer.
Senn,
H. J., Thürlimann, B., Goldhirsch, A., Wood, W. C., Gelber, R. D., and Coates,
A. S.
Breast
12(6), 569-582. 2003.
The
best use of adjuvant endocrine treatments.
Pritchard,
K. I.
Breast
12(6), 497-508. 2003.
Adjuvant
therapy for older women with breast cancer.
Muss,
H. B.
Breast
12(6), 550-557. 2003.
Changing
role of the oestrogen receptor in the life and death of breast cancer cells.
Jordan,
V. C., Osipo, C., Schafer, J. M., Fox, J. E., Cheng, D., and Liu, H.
Breast
12(6), 432-441. 2003.
New
findings about endocrine therapy for breast cancer.
Davidson,
N. E., Visvanathan, K., and Emens, L.
Breast
12(6), 368-372. 2003.
Suppression
of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds.
Eng,
E. T., Ye, J. J., Williams, D., Phung, S., Moore, R. E., Young, M. K.,
Gruntmanis, U., Braunstein, G., and Chen, S.
Cancer
Research 63(23), 8516-8522. 2003.
The
impact of adjuvant therapy for breast cancer on cognitive function: Current
evidence and directions for research.
Rugo,
H. S. and Ahles, T.
Seminars
in Oncology 30(6), 749-762. 2003.
Second
cancers after breast cancer treatment.
Matesich,
S. M. A. and Shapiro, C. L.
Seminars
in Oncology 30(6), 740-748. 2003.
Adjuvant
endocrine therapy compared with no systemic therapy for elderly women with
early breast cancer: 21-year results of international breast cancer study group
trial IV.
Crivellari,
D., Price, K., Gelber, R. D., Castiglione, Gertsch M., Rudenstam, C. M.,
Lindtner, J., Fey, M. F., Senn, H. J., Coates, A. S., Collins, J., and
Goldhirsch, A.
Journal
of Clinical Oncology 21(24), 4517-4523. 2003.
New
developments in endocrine therapy - Role of adjuvant therapy for early breast
cancer.
Grana,
G.
Cancer
Nursing 26(6 Supplement), 4S-9S. 2003.
Preventing
breast Ca with aromatase inhibitors.
Mitwally,
M. F. and Casper, R. F.
Contemporary
Ob/gyn 48(12), 68-70, 73, 76, 79. 2003.
Genotoxic
metabolites of estradiol in breast: potential mechanism of estradiol induced
carcinogenesis.
Yue,
W., Santen, R. J., Wang, J. P., Li, Y., Verderame, M. F., Bocchinfuso, W. R.,
Korach, K. S., Devanesan, P., Todorovic, R., Rogan, E. G., and Cavalieri, E. L.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 477-486. 2003.
Sources
of estrogen and their importance.
Simpson,
E. R.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 225-230. 2003.
The
effects of hormone therapy on cognition in breast cancer.
Shilling,
V., Jenkins, V., Fallowfield, L., and Howell, T.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 405-412. 2003.
Breast
cancer prevention - clinical trials strategies involving aromatase inhibitors.
Goss,
P. E.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 487-493. 2003.
Aromatase
inhibitors as adjuvant therapies in patients with breast cancer.
Coombes,
R. C., Gibson, L., Hall, E., Emson, M., and Bliss, J.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 309-311. 2003.
'Arimidex'
(anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with
early breast cancer-efficacy overview.
Buzdar,
A. U.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 399-403. 2003.
Letrozole
versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant
therapy.
Smith,
I. E.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 289-293. 2003.
Hormonal
effects of aromatase inhibitors: focus on premenopausal effects and interaction
with tamoxifen.
Dowsett,
M. and Haynes, B. P.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 255-263. 2003.
Focus
on anastrozole and breast cancer.
Mokbel,
K.
Current
Medical Research and Opinion 19(8), 683-688. 2003.
New
technologies for diagnosis and treatment of breast cancer: Meeting highlights
from the fourth Milan Breast Cancer Conference (Milan, June 5-7 2002).
Veronesi,
U., Goldhirsch, A., Costa, A., and Zurrida, S.
Breast 12(3), 223, 224-223, 230. 2003.
The
time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen,
Alone or in Combination) trial.
Locker, G. and Eastell, R., 1. 2003.
A
review of selective estrogen receptor modulators and national surgical adjuvant
breast and bowel project clinical trials.
Smith,
R. E.
Seminars in Oncology 30(5 Supplement), 4-13. 2003.
Follow-up
care of breast cancer survivors.
Hurria,
A. and Hudis, C.
Critical
Reviews in Oncology/Hematology 48(1), 89-99. 2003.
Neuropsychological
functioning following systemic treatment in women treated for breast cancer: a
review.
Morse,
R., Rodgers, J., Verrill, M., and Kendell, K.
European
Journal of Cancer 39(16), 2288-2297. 2003.
Aromatase
inhibitors versus tamoxifen for management of postmenopausal breast cancer in
the advanced disease and neoadjuvant settings.
Ingle,
J. N. and Suman, V. J.
Journal
of Steroid Biochemistry and Molecular Biology 86(3-5), 313-319. 2003.
Adjuvant
aromatase inhibitors - Are we there yet?
Gini,
F. and Fleming, M. D.
Cancer 98(9), 1779-1781. 2003.
Treatment
of ductal carcinoma in situ of the breast: Review of recent advances and future
prospects.
Mokbel,
K.
International
Journal of Fertility and Menopausal Studies 48(5), 217-225. 2003.
Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early-stage breast cancer -.
Cancer
98(9), 1802-1810. 2003.
Canadian
oncologists' attitudes towards guideline development and outcomes of clinical
trials based on results of the ATAC trial.
Verma,
S. and Trudeau, M.
Breast Cancer Research and Treatment 82(Suppl 1),
S159, Abs. 2003.
Canadian
cost-effectiveness analysis of anastrozole versus tamoxifen in early breast
cancer.
Verma,
S., Rocchi, A., and Cheung, S.
Breast Cancer Research and Treatment 82(Suppl 1),
S157, Abs. 2003.
Cost-effectiveness
projections of anastrozole vs. tamoxifen as initial adjuvant therapy in
ER-positive early breast cancer.
Hillner,
B. E.
Breast Cancer Research and Treatment 82(Suppl 1),
S156, Abs. 2003.
Adjuvant
endocrine treatment of breast cancer beyond St. Gallen 2003.
Gerber,
B.
Zentralblatt
für Gynakologie 125(9), 315-321. 2003.
Effect
of anastrozole on bone mineral density: 2-year results of the 'arimidex'
(anastrozole), tamoxifen, alone or in combination (ATAC) trial.
Howell,
A.
Breast Cancer Research and Treatment 82(Suppl 1), S27,
Abs. 2003.
The
endometrial cancer data from the ATAC (arimidex, tamoxifen, alone or in
combination) trial indicates a protective effect of anastrozole (arimidex) upon
the endometrium.
Duffy,
S. R. and Greenwood, M.
Breast Cancer Research and Treatment 82(Suppl 1), S29,
Abs. 2003.
Advances
in estrogen receptor biology: prospects for improvements in targeted breast
cancer therapy.
Shao,
W. L. and Brown, M.
Breast
Cancer Research 6(1), NIL. 2003.
Greater
Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than
with tamoxifen (T) or anastrozole plus tamoxifen (c) in the IMPACT trial: a
potential predictor of relapse-free survival.
Dowsett,
M. and Smith, I.
Breast
Cancer Research and Treatment 82(Suppl 1), s6, abs. 2003.
Comparison
of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment
of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women:
the IMPACT trial.
Smith,
I. and Dowsett, M.
Breast
Cancer Research and Treatment 82(Suppl 1), s6, abs. 2003.
Analysis
of time to recurrence in the ATAC (Arimidex, tamoxifen alone or in combination)
trial according to estrogen receptor and progesterone receptor status.
Dowsett,
M.
Breast
Cancer Research and Treatment 82(Suppl 1), s7, abs. 2003.
Aromatase
inhibitors and breast cancer - Introduction.
Hudis,
C.
Seminars in Oncology 30(4 Supplement), 1-2. 2003.
Effect
of anastrozole on bone mineral density: 2-year results of the 'Arimidex'
(anastrozole), tamoxifen, alone or in combination (ATAC) trial.
Eastell,
R.
Journal of Bone and Mineral Research 18(Suppl 2),
S312, Abs. 2003.
Hormonal
therapy of breast cancer.
Current Problems in Cancer 27(6), 279-331. 2003.
An
assessment of the updated results from the arimidex, tamoxifen, alone or in
combination (ATAC) trial: An evidence-based medicine approach.
Edwards,
S. J.
Value in Health 6(6), 731, Abs. 2003.
Health
economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in
adjuvant treatment of postmenopausal hormone receptor positive early breast
cancer.
Annemans,
L., Moeremans, K., and Lamarque, H.
Value in Health 6(6), 625, Abs. 2003.
Aromatase
inhibitors in early breast cancer treatment.
Mauriac,
L. and Smith, I.
Seminars
in Oncology 30(4 Supplement), 46-57. 2003.
Origin
and characteristics of adverse events in aromatase inhibition therapy for
breast cancer.
Dowsett,
M.
Seminars
in Oncology 30(4 Supplement), 58-69. 2003.
Aromatase
inhibitor development and hormone therapy: A perspective.
Brodie,
A.
Seminars
in Oncology 30(4 Supplement), 12-22. 2003.
Treatment
of primary breast cancer: recent developments.
Dall,
P. and Schutt, G.
Gynakologe
36(9), 767, 770-767, 775. 2003.
Chemoprevention
of breast cancer and the trials of the National Surgical Adjuvant Breast and
Bowel Project and others.
Smith,
R. E. and Good, B. C.
Endocrine
Related Cancer 10(3), 347-357. 2003.
Coagulopathic
complications in breast cancer.
Caine,
G. J., Stonelake, P. S., Rea, D., and Lip, G. Y. H.
Cancer
98(8), 1578-1586. 2003.
Inhibition
of aromatase: insights from recent studies.
Santen,
R. J.
Steroids
68(7-8), 559-567. 2003.
Quality
of life in oncological gynaecology - a report with the results of the
ASCO-meeting 2002.
Sehouli,
J., Konsgen, D., Klapp, C., Walle, U., Katsares, I., Oskay, G., Mustea, A.,
Buhling, K., and Lichtenegger, W.
Geburtshilfe
und Frauenheilkunde 63(8), 752-757. 2003.
Prevention
of breast cancer using SERMs and aromatase inhibitors.
Strasser,
Weippl K. and Goss, P. E.
Journal
of Mammary Gland Biology and Neoplasia 8(1), 5-18. 2003.
Aromatase
inhibitors for breast cancer: Lessons from the laboratory.
Johnston,
S. R. D. and Dowsett, M.
Nature
Reviews Cancer 3(11), 821-831. 2003.
New
approaches to the endocrine prevention and treatment of breast cancer.
Howell,
A., Howell, S. J., and Evans, D. G.
Cancer
Chemotherapy and Pharmacology 52(Suppl 1), S39-S44. 2003.
ATAC
trial did not report interim results.
Baum,
M., Buzdar, A., and Howell, A.
BMJ British Medical Journal 327(7422), 1050. 2003.
Risk
of osteoporosis after adjuvant therapy for breast cancer.
Hadji,
P., Bock, K., Jackisch, C., and Wagner, U.
Gynakologe
36(8), 671-3, 676. 2003.
Meeting
highlights: Updated international expert consensus on the primary therapy of
early breast cancer.
Goldhirsch,
A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., and Senn, H. J.
Journal
of Clinical Oncology 21(17), 3357-3365. 2003.
Sequential
hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or
anastrozole.
Carlson,
R. W. and Henderson, I. C.
Breast
Cancer Research and Treatment 80(Suppl 1), S19-S26. 2003.
New
approaches to breast cancer therapy.
Hortobagyi,
G. N.
Breast
Cancer Research and Treatment 80(Suppl 1), S1-S2. 2003.
Issues
in hormonal treatment of early breast cancer - The ATAC trial - is there enough
evidence to change clinical practice?
Henderson,
Aapro, Forbes, Hortobagyi, Klijn, Marang, Anon, and Bell
Breast Cancer Research and Treatment 80(Suppl 1),
13-18. 2003.
The
future shape of hormonal therapy for metastatic breast cancer after adjuvant
tamoxifen or anastrozole.
Forbes,
Henderson, Carlson, Rutgers, Hortobagyi, and Klijn
Breast Cancer Research and Treatment 80(Suppl 1),
S27-S28. 2003.
Three
years' follow-up from the ATAC trial is sufficient to change clinical practice:
a debate.
Aapro,
M. S. and Forbes, J. F.
Breast
Cancer Research and Treatment 80(Suppl 1), S3-S11. 2003.
Advances
in breast cancer treatment and prevention: preclinical studies on aromatase
inhibitors and new selective estrogen receptor modulators (SERMs).
Schiff,
R., Chamness, G. C., and Brown, P. H.
Breast
Cancer Research 5(5), 228-231. 2003.
A
randomized trial of letrozole in postmenopausal women after five years of
tamoxifen therapy for early-stage breast cancer.
Goss,
P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J.,
Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B.,
Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Therasse, P., Palmer,
M. J., and Pater, J. L.
New
England Journal of Medicine 349(19), 1-10. 2003.
Clinical
pharmacokinetics of aromatase inhibitors and inactivators.
Lonning,
P. E.
Clinical Pharmacokinetics 42(7), 619-631. 2003.
Introduction:
Setting new standards in aromatase inhibitor therapy.
Mouridsen,
H. T.
American Journal of Clinical Oncology 26(4
Supplement), S1-S2. 2003.
Emerging
role of aromatase inhibitors in the adjuvant setting.
Goss,
P. E.
American
Journal of Clinical Oncology 26(4 Supplement), S27-S33. 2003.
Role
of biologic markers in patient selection and application to disease prevention.
Dowsett,
M. and Ellis, M. J.
American
Journal of Clinical Oncology 26(4 Supplement), S34-S39. 2003.
Applicability
of the intratumor aromatase preclinical model to predict clinical trial results
with endocrine therapy.
Brodie,
A. H. and Mouridsen, H. T.
American
Journal of Clinical Oncology 26(4 Supplement), S17-S26. 2003.
Positive
lymph nodes - Search for a standard.
Bighin,
C., Catzeddu, T., and Venturini, M.
Tumori (Suppl S), S6-S8. 2003.
Adjuvant
aromatase inhibitors. Are we there yet?
Fleming,
G. F.
Cancer . 2003.
Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early-stage breast cancer. Results of
the ATAC trial efficacy and safety update analyses.
Baum,
M., Budzar, A., Cuzick, J., Forbes, J., Houghton, J., Williams, N., Howell, A.,
Sahmoud, T., and Hellmund, R.
Cancer . 2003.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer
trial in postmenopausal (PM) women.
Tobias,
J. S.
European Journal of Cancer 38(Suppl 3), S92, Abs.
2003.
Update
on new studies in Europe.
Cuzick,
J.
European Journal of Cancer 38(Suppl 3), S44, S43, Abs.
2003.
Current
status of aromatase inhibitors.
Baum,
M.
European Journal of Cancer 38(Suppl 3), S44, Abs.
2003.
Intravenous
administration of zoledronic acid prevents the bone loss and reduction of mechanical
properties induced by aromatase inhibition or surgical ovariectomy in rats.
Gasser,
J. A., Green, J. R., Shen, V., Leininger, R., Bhatnagar, A. S., and Evans, D.
B.
Bone 32(5 Supplement), S202, Abs. 2003.
Hormonal
therapy: introduction.
Smith,
I. E.
Breast 12(Suppl 2), S1. 2003.
Challenges
in the endocrine management of breast cancer.
Mouridsen,
H. T., Rose, C., Brodie, A. H., and Smith, I. E.
Breast
12(Suppl 2), S2-S19. 2003.
The
ATAC (anastrozole, Tamoxifen, Alone or in Combination) trial ? an efficacy
update, focusing on breast cancer (BC) events, based on a median follow-up of
47 months.
Klijn,
J.
Program/proceedings - American Society of Clinical
Oncology 22 Pages, 85, Abs. 2003.
Anastrozole
for ductal carcinoma in situ.
Cuzick,
J., O'Neill, C., Howell, T., and Forbes, J.
Lancet 362(9386), 832-833. 2003.
Diagnosis
and treatment of breast cancer in the elderly.
Holmes,
C. E. and Muss, H. B.
CA
A Cancer Journal For Clinicians 53(4), 227-244. 2003.
Future
directions in the endocrine therapy of breast cancer.
Hortobagyi,
G. N.
Breast
Cancer Research and Treatment 80(Suppl 1), S37-S39. 2003.
Advances
in endocrine treatments for postmenopausal women with metastatic and early
breast cancer.
Buzdar,
A. U.
Oncologist
8(4), 335-341. 2003.
The
current status of aromatase inhibitors in the management of breast cancer.
Baum,
M. and Buzdar, A.
Surgical
Clinics of North America 83(4), 973-94, XI. 2003.
American
society of clinical oncology technology assessment working group update: Use of
aromatase inhibitors in the adjuvant setting.
Winer,
E. P., Hudis, C., Burstein, H. J., Bryant, J., Chlebowski, R. T., Ingle, J. N.,
Edge, S. B., Mamounas, E. P., Gelber, R., Gralow, J., Goldstein, L. J.,
Pritchard, K. I., Braun, S., Cobleigh, M. A., Langer, A. S., Perotti, J.,
Powles, T. J., Whelan, T. J., and Browman, G. P.
Journal of Clinical Oncology 21(13), 2597-2599. 2003.
ATAC
trial: Reports of interim results can be misleading--a reply.
Baum,
M.
BMJ British Medical Journal (July 14), eletter. 2003.
Phase
III Clinical Trials in Oncology - 20-21 January 2003, London, UK.
Buyse,
M.
IDrugs (London) 6(3), 187-190. 2003.
Treatment
of older breast cancer patients with high recurrence risk.
Crivellari,
D., Spazzapan, S., Lombardi, D., Berretta, M., Magri, M. D., Sorio, R.,
Scalone, S., and Veronesi, A.
Critical
Reviews in Oncology/Hematology 46(3), 241-246. 2003.
Update
on the current use of hormonals as therapy in advanced breast cancer.
Vogel,
C. L.
Anti
Cancer Drugs 14(4), 265-273. 2003.
Present
and future of adjuvant hormone therapy in breast cancer: clinical evidence and
clinical trials.
Laborda,
A. Z., de Vidales, C. M., and Perez, Torrubia A.
Revista Clinica Espanola 203(4), 202-206. 2003.
Is
low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu,
K. and Brown, P.
Journal of the National Cancer Institute 95(11),
766-767. 2003.
Breast
cancer - Have we been chasing the wrong target?
Dooley,
W. C.
Journal of Surgical Oncology 83(2), 57-60. 2003.
Bone
density changes in Japanese breast cancer patients receiving anastrozole.
Tominaga,
S., Shibata, K., Matsuda, Y., and Kobayashi, T.
Program/proceedings - American Society of Clinical
Oncology 22 Pages, 77, Abs308. 2003.
Hormonal
therapy in postmenopausal women with breast cancer.
Campos,
S. M. and Winer, E. P.
Oncology
(Basel) 64(4), 289-299. 2003.
ATAC
trial: reporting interim results is not helpful.
Goodare,
H., Dimmer, C., and Page, K.
BMJ British Medical Journal 326(7402), 1329. 2003.
Drug
therapy: Aromatase inhibitors in breast cancer.
Smith,
I. E. and Dowsett, M.
New England Journal of Medicine 348(24), 2431-2442.
2003.
The
time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen,
Alone or in Combination) trial.
Locker,
G. Y. and Eastell, R.
Program/proceedings - American Society of Clinical
Oncology 22 Pages, 25, Abs. 2003.
The
place of aromatase inhibitors in the management of breast cancer following
preliminary results from the ATAC trial.
Carpenter,
R.
Cancer Investigation 21(Suppl 1), 53-4, Abs. 2003.
Role
of tamoxifen (TAM).
Boyle,
P. and Cuzick, J.
Breast 12(3), 225-226. 2003.
The
adjuvant treatment of breast cancer.
Kelleher,
M. and Miles, D.
International
Journal of Clinical Practice 57(3), 195-199. 2003.
Anti-oestrogenic
chemoprevention of breast cancer - the need to progress.
Powles,
T. J.
European
Journal of Cancer 39(5), 572-579. 2003.
Aromatase
inhibitors as adjuvant therapy for breast cancer.
Maass,
N. and Jonat, W.
Gynakologe
36(2), 103-109. 2003.
Endocrine
therapy for metastatic breast cancer.
Loibl,
S., Von Minckwitz, G., and Kaufmann, M.
Gynakologe
36(2), 110-2, 114. 2003.
New
paradigms in adjuvant systemic therapy of breast cancer.
Thomas,
E. and Hortobagyi, G. N.
Endocrine
Related Cancer 10(1), 75-89. 2003.
Towards
optimal management of ductal carcinoma in situ of the breast.
Mokbel,
K.
European
Journal of Surgical Oncology 29(2), 191-197. 2003.
Randomized
trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant
treatment in postmenopausal breast cancer patients with hormone
receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group
trial 6.
Schmid,
M., Jakesz, R., Samonigg, H., Kubista, E., Gnant, M., Menzel, C., Seifert, M.,
Haider, K., Taucher, S., Mlineritsch, B., Steindorfer, P., Kwasny, W., Stierer,
M., Tausch, C., Fridrik, M., Wette, V., Steger, G., and Hausmaninger, H.
Journal
of Clinical Oncology 21(6), 984-990. 2003.
A
7-month (MTH) safety updaye from the ATAC ('Arimidex', Tamoxifen, Alone or in
Combination) trial: Anastrozole (A) maintains a beneficial side-effect profile
compared to tamoxifen (T).
Howell,
A.
Breast 12(1 (Feb)), S47, Abs. 2003.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal
women with early breast cancer - Update efficacy results based on median
follow-up of 47 months.
Cuzick,
J.
Breast 12(1 (Feb)), S47, Abs. 2003.
American
Society of Clinical Oncology Technology Assessment Working Group update: Use of
aromatase inhibitors in the adjuvant setting.
Winer,
E. P., Hudis, C., Burstein, H. J., Bryant, J., Chlebowski, R. T., Ingle, J. N.,
Edge, S. B., Mamounas, E. P., Gelber, R., Gralow, J., Goldstein, L. J.,
Pritchard, K. I., Braun, S., Cobleigh, M. A., Langer, A. S., Perotti, J.,
Powles, T. J., Whelan, T. J., and Browman, G. P.
Journal of Clinical Oncology 21(13), 1-3. 2003.
Cost-effectiveness
projections of anastrozole (AN) vs tamoxifen (T) as initial adjuvant therapy in
ER-positive early breast cancer using data from the ATAC trial.
Hillner,
B. E.
Breast 12(1 (Feb)), S44-45, Abs. 2003.
Phase
III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen
and anastrozole in hormone-responsive postmenopausal breast cancer patients
(National Surgical Adjuvant Study of Breast Cancer NSAS BC 03).
Takatsuka,
Y. and Aihara, T.
Breast 12(1 (Feb)), S44, Abs. 2003.
Intravenous
administration of zoledronic acid prevents the bone loss and reduction of
mechanical properties inducedby aromatase inhibition or surgical ovariectomy in
rats.
Gasser,
J. A., Green, J. R., Shen, V., Leininger, R., Bhatnagar, A. S., and Evans, D.
B.
Breast 12(1 (Feb)), S42, Abs. 2003.
Does
treatment for breast cancer affect cognition? A pilot study using a pragmatic
cognitive assessment package.
Jenkins,
V., Fallowfield, L., Shilling, V., Howell, A., and Hutton, S.
Breast 12(1 (Feb)), S42, Abs. 2003.
Assessing
the quality of life of postmenopausal women randmized into the ATAC
('arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial.
Fallowfield,
L. and Cella, D.
Breast 12(1 (Feb)), S42, Abs. 2003.
Fewer
endometrial abnormalities with anastrozole than tamoxifen: Endometrial
subprotocol results from the ATAC ('Arimidex', Tamoxifen, Alone or in
Combination) early breast cancer trial in postmenopausal patients.
Duffy,
S.
Breast 12(1 (Feb)), S39, Abs. 2003.
The
best use of adjuvant endocrine treatments.
Pritchard,
K., I
Breast 12(1 (Feb)), S10-S11, Abs. 2003.
New
data on endocrine treatments.
Davidson,
N. E.
Breast 12(1 (Feb)), S4, Abs. 2003.
Anastrozole
(Arimidex) vs. tamoxifen for treatment of early breast cancer.
Medical Letter on Drugs and Therapeutics 45(1152),
22-23. 2003.
Medical
oncology.
Aapro,
M. S.
Medecine
et Hygiene 61(2419), 37-8, 40, 43. 2003.
News
in the medical treatment of breast cancer.
Piccart,
M., Dochy, E., and Cardoso, F.
Bulletin
du Cancer 90(1), 46-52. 2003.
Current
status of selective estrogen receptor modulators (SERMs).
Conzen,
S. D.
Cancer Journal 9(1), 4-14. 2003.
Current
and future status of adjuvant therapy for breast cancer.
Coleman,
R. E.
Cancer
97(3 Supplement), 880-886. 2003.
Local
failure and prognostic factors in ductal carcinoma in situ: concentration on
recent publications.
Zellars,
R. and Wolff, A. C.
Current
Opinion in Obstetrics and Gynecology 15(1), 9-12. 2003.
Clinical
differences among the aromatase inhibitors.
Ligibel,
J. A. and Winer, E. P.
Clinical
Cancer Research 9(1 Pt 2 Supplement), 473S-479S. 2003.
Pharmacology
and pharmacokinetics of the newer generation aromatase inhibitors.
Buzdar,
A. U.
Clinical
Cancer Research 9(1 Pt 2 Supplement), 468S-472S. 2003.
Preoperative
models to evaluate endocrine strategies for breast cancer.
Dowsett,
M.
Clinical
Cancer Research 9(1 Pt 2 Supplement), 502S-510S. 2003.
Adjuvant
endocrine therapy in postmenopausal breast cancer.
Ingle,
J. N.
Clinical
Cancer Research 9(1 Pt 2 Supplement), 480S-485S. 2003.
Second
International Conference on Recent Advances and Future Directions in Endocrine
Manipulation of Breast Cancer: Summary consensus statement.
Come,
S. E., Buzdar, A. U., Arteaga, C. L., Brodie, A. M., Davidson, N. E., Dowsett,
M., Ingle, J. N., Johnston, S. R. D., Lee, A. V., Osborne, C. K., Pritchard, K.
I., Vogel, V. G., Winer, E. P., and Hart, C. S.
Clinical Cancer Research 9(1 Pt 2 Supplement), 443S-446S.
2003.
Predictions
from a preclinical model: Studies of aromatase inhibitors and antiestrogens.
Brodie,
A., Jelovac, D., and Long, B. J.
Clinical
Cancer Research 9(1 Pt 2 Supplement), 455S-459S. 2003.
Drug
therapy: Selective estrogen-receptor modulators - Mechanisms of action and
application to clinical practice.
Riggs,
B. L. and Hartmann, L. C.
New England Journal of Medicine 348(7), 618-629. 2003.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal
women with early breast cancer, updated efficacy results based on a median
follow-up of 47 months.
Buzdar,
A.
Breast
Cancer Research and Treatment 77(3), 295, Abs. 2003.
Breast
surgery in the ATAC trial: women from the United States are more likely to have
mastectomy.
Locker,
G., Sainsbury, R., and Cuzick, J.
Breast Cancer Research and Treatment 76(December
Supplement), S35, Abs. 2002.
A
mechanism of drug resistance to tamoxifen in breast cancer.
Schafer,
J. M., Bentrem, D. J., Takei, H., Gajdos, C., Badve, S., and Jordan, V. C.
Journal
of Steroid Biochemistry and Molecular Biology 83(1-5), 75-83. 2002.
The
menopause, hormone replacement therapy and breast cancer.
Marsden,
J.
Journal
of Steroid Biochemistry and Molecular Biology 83(1-5), 123-132. 2002.
Anastrozole:
An aromatase inhibitor as a potential preventative agent in women at high risk
of developing breast cancer.
Buzdar,
A. U.
Cancer Epidemiology Biomarkers and Prevention 11(10 Pt
2), 1245S. 2002.
Fulvestrant
('Fasiodex') - a new treatment option for patients progressing on prior
endocrine therapy.
Morris,
C. and Wakeling, A.
Endocrine
Related Cancer 9(4), 267-276. 2002.
Cognitive
assessment of women receiving hormone therapy for breast cancer.
Shilling,
V., Jenkins, V., Fallowfield, L., and Howell, T.
Psycho Oncology 11(6), 556. 2002.
The
ATAC-trial.
Sainsbury,
R.
European Journal of Cancer 38(Suppl 6), S81-2, Abs.
2002.
The
arimidex, alone or in combination (ATAC) adjuvant breast cancer trial: Baseline
endometrial sub-protocol data.
Duffy,
S. and Jackson, T. L.
European Journal of Cancer 38(Suppl 6), S83, Abs.
2002.
Rationale
for a study testing aromatase inhibitors in prevention and DCIS.
Cuzick,
J.
European Journal of Cancer 38(Suppl 6), S81, Abs.
2002.
Endometrial
evaluation is a very important tool in the management of breast cancer patients.
Berliere,
M., Galant, C., Charles, A., Brichard, V., Piette, P., and Donnez, J.
European Journal of Cancer 38(Suppl 6), S67-S68. 2002.
Systemic
therapy.
Wolff,
A. C.
Current
Opinion in Oncology 14(6), 600-608. 2002.
Neoadjuvant
endocrine therapy of breast cancer: a surgical perspective.
Dixon,
J. M., Anderson, T. J., and Miller, W. R.
European
Journal of Cancer 38(17), 2214-2221. 2002.
Understanding
and managing breast cancer: Quo vadis?
Vaidya,
J. S.
National Medical Journal of India 15(5), 252-256.
2002.
Breast
cancer prevention.
Mokbel,
K.
British Journal of General Practice 52(485), 972-973.
2002.
Anastrozole
- In early breast cancer.
Wellington,
K. and Faulds, D. M.
Drugs
62(17), 2483-2490. 2002.
Breast
cancer: Aromatase inhibitors take on tamoxifen.
Dowsett,
M. and Howell, A.
Nature Medicine 8(12), 1341-1344. 2002.
Anastrozole
- Commentary.
Mccarthy,
N.
Drugs 62(17), 2491. 2002.
Anastrozole
- Commentary.
Buzdar,
A. U.
Drugs 62(17), 2491-2492. 2002.
Endocrine
treatment and prevention of breast and gynaecological cancers.
Neven,
P., Vergote, I., Van Ginderachter, J., Van Dam, P., Tjalma, W., De Rop, C., and
De Prins, F.
European Journal of Cancer 38(Suppl 6), S1-S11. 2002.
Beneficial
side-effect profile of anastrozole compared with tamoxifen confirmed by
additional 7 months of exposure data: a safety update from the Arimidex,
Tamoxifen, Alone or in Combination (ATAC) trial.
Sainsbury,
R.
Breast
Cancer Research and Treatment 76(December Supplement), S156, Abs. 2002.
ATAC
(Arimidex, Tamoxifen, Alone or in Combination) trial-anastrozole is superior to
tamoxifen as adjuvant treatment in postmenopausal women with early breast
cancer.
Bianco,
A. R.
Breast
Cancer Research and Treatment 76(December Supplement), S155, Abs. 2002.
Advances
in endocrine therapy of metastatic breast cancer.
Gradishar,
W. J. and Morrow, M.
British Journal of Surgery 89(12), 1489-1492. 2002.
The
ATAC (Arimidex(TM), Tamoxifen, Alone or in Combination) adjuvant breast cancer
trial in postmenopausal patients: factors influencing the success of patient
recruitment.
Baum,
M.
European
Journal of Cancer 38(15), 1984-1986. 2002.
Progress
in the treatment of breast cancer in the elderly.
Aapro,
M. S.
Annals of Oncology 13(Suppl 4), 207-210. 2002.
Questions
about anastrozole for early breast cancer.
Stasi,
R., Terzoli, E., Thornton, H., and Baum, M.
Lancet 360(9348), 1890-1891. 2002.
Aromatase
inhibitors.
Grubjesic,
S., Moriarty, R. M., and Pezzuto, J. M.
Expert
Opinion on Therapeutic Patents 12(11), 1647-1661. 2002.
Breast
cancer chemoprevention - An update.
Mokbel,
K. and Singh, Ranger G.
Current
Medical Research and Opinion 18(6), 329-331. 2002.
Breast
cancer - An oncologist's view.
Bergh,
J.
European Radiology 12(8), E13-4, Abs. 2002.
A
new day dawns: women without oestrogen or is a balance best?
Jordan,
V. C.
Breast
Cancer Research 4(6), 218-221. 2002.
Has
tamoxifen had its day?
Baum,
M.
Breast
Cancer Research 4(6), 213-217. 2002.
Anastrozole
is superior to tamoxifen as first-line therapy in hormone receptor-positive
advanced breast carcinoma.
Gluck,
S., Bonneterre, J., Buzdar, A., Nabholtz, J. M., Robertson, J., Thurlimann, B.,
Von Euler, M., Sahmoud, T., Steinborg, M., and Webster, A.
Cancer 95(11), 2442-2444. 2002.
An
overview of the pharmacology and pharmacokinetics of the newer generation
aromatase inhibitors anastrozole, letrozole, and exemestane
.
Buzdar,
A. U., Robertson, J. F. R., Eiermann, W., and Nabholtz, J. M.
Cancer
95(9), 2006-2016. 2002.
Hormonal
risk factors for breast cancer: identification, chemoprevention, and other
intervention strategies.
Clamp,
A., Danson, S., and Clemons, M.
Lancet
Oncology 3(10), 611-619. 2002.
Assessing
the quality of life (QoL) of postmenopausal (PM) women randomized into the ATAC
(Arimidex, tamoxifen, Alone or in Combination) adjuvant breast cancer trial
(ATAC Trialists Group).
Fallowfield,
L. and Cella, D.
Annals
of Oncology 13(Suppl 5), 40-1, Abs. 2002.
Complete author abstract may be found at:
http://annonc.oupjournals.org/cgi/reprint/13/suppl_5/33.pdf
Fewer
endometrial abnormalities with anastrozole than tamoxifen: Endometrial
subprotocol results from the ATAC (Arimidex, tamoxifen, Alone or in
Combination) early breast cancer (EBC) trial in postmenopausal (PM) patients
(pts).
Duffy,
S. and Jackson, T.
Annals
of Oncology 13(Suppl 5), 39, Abs. 2002.
Complete author abstract may be found at:
http://annonc.oupjournals.org/cgi/reprint/13/suppl_5/33.pdf
Results
of the Arimidex (anastrozole, A), tamoxifen (T), alone or in combination (C)
(ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC
Trialists Group).
Eastell,
R. and Adams, J.
Annals
of Oncology 13(Suppl 5), Abs. 2002.
Complete author abstract may be found at: http://annonc.oupjournals.org/cgi/reprint/13/suppl_5/31.pdf
Anastrozole
(A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with
early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen,
Alone or in Combination) trial (on behalf of the ATAC Trialists Group).
Baum,
M.
Annals
of Oncology 13(Suppl 5), 32, Abs. 2002.
Complete author abstract may be found at:
http://annonc.oupjournals.org/cgi/reprint/13/suppl_5/31.pdf
A
new standard in adjuvant hormonal therapy of breast cancer? - First results of
the ATAC trial.
Apffelstaedt,
J.
South African Medical Journal 92(7), 560. 2002.
Innovative
gynecologic oncology.
Dall,
R.
Gynakologe
35(9), 867-871. 2002.
ASCO
update on breast cancer chemoprevention.
Inpharma (1355), 3. 2002.
Cancer
prevention science and practice.
Lippman,
S. M. and Hong, W. K.
Cancer Research 62(18), 5119-5125. 2002.
The
status of breast cancer management: Challenges and opportunities.
Hortobagyi,
G. N.
Breast
Cancer Research and Treatment 75(4 Supplement), S61-S65. 2002.
Choosing
between endocrine therapy and chemotherapy - or is there a role for combination
therapy?
Forbes,
J. F., Gradishar, W. J., and Ravdin, P. M.
Breast
Cancer Research and Treatment 75(4 Supplement), S37-S44. 2002.
Sequencing
of endocrine therapies in breast cancer - integration of recent data.
Carlson,
R. W.
Breast
Cancer Research and Treatment 75(4 Supplement), S27-S32. 2002.
New
generation aromatase inhibitors - from the advanced to the adjuvant setting.
Buzdar,
A. U.
Breast
Cancer Research and Treatment 75(4 Supplement), S13-S17. 2002.
New
drugs for breast cancer.
Smith,
I. E.
Lancet 360(9335), 790-792. 2002.
Anastrozole
versus tamoxifen as first-line therapy for advanced breast cancer: methodologic
issues.
Winquist,
E., Bramwell, V., Vandenberg, T., Bonneterre, J., Nabholtz, J.-M., Budzar, A.,
Robertson, J., Thurlimann, B., Steinberg, M., Webster, A., and Von Euler, M.
Journal of Clinical Oncology 20(17), 3748-3750. 2002.
Upstaging
tamoxifen? New classes of drugs emerging for breast cancer.
Twombly,
R.
Journal of the National Cancer Institute 94(7),
474-475. 2002.
American
Society of Clinical Oncology technology assessment of pharmacologic
interventions for breast cancer risk reduction including tamoxifen, raloxifene,
and aromatase inhibition.
Chlebowski,
R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G. I.
I., Burstein, H. J., Eisen, A., Lipkus, I., and Pfister, D. G.
Journal
of Clinical Oncology 20(15), 3328-3343. 2002.
To
block estrogen's synthesis or action: That is the question.
Santen,
R. J.
Journal of Clinical Endocrinology and Metabolism
87(7), 3007-3012. 2002.
A
rose is no longer a rose.
Henderson,
I. C.
Journal of Clinical Oncology 20(16), 3365-3368. 2002.
American
Society of Clinical Oncology technology assessment on the use of aromatase
inhibitors as adjuvant therapy for women with hormone receptor-positive breast
cancer: Status report 2002.
Winer,
E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S.
B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., Braun, S.,
Cobleigh, M. A., Langer, A. S., Perotti, J., Powles, T. J., Whelan, T. J., and
Browman, G. P.
Journal
of Clinical Oncology 20(15), 3317-3327. 2002.
Evolving
uses of hormonal agents for breast cancer therapy.
Cummings,
F. J.
Clinical
Therapeutics 24(Suppl C), C3-C25. 2002.
Anastrozole
is superior to tamoxifen in the treatment of postmenopausal women with early
breast cancer - first results of the ATAC ('Arimidex', Tamoxifen, alone or in
combination) trial.
Sainsbury,
R.
International Journal of Cancer (Suppl 13), 137. 2002.
The
ATAC ('Arimidex', Tamoxifen, alone or in combination) early breast cancer trial
in postmenopausal patients: endometrial sub-protocol results.
Duffy,
S. and Jackson, T.
International Journal of Cancer (Suppl 13), 137-138.
2002.
Aromatase
inhibitors and inactivators for breast cancer therapy.
Lonning,
P. E.
Drugs
& Aging 19(4), 277-298. 2002.
Aromatase
inhibitors in breast cancer: Current and evolving roles.
Hill,
J. and Moore, H.
Cleveland
Clinic Journal of Medicine 69(7), 561-567. 2002.
The aromatase inhibitors are established first-line
drugs for treating metastatic breast cancer in postmenopausal women, and are
gaining acceptance as adjuvant treatment as well
Anti-aromatase
agents in the treatment and prevention of breast cancer.
Goss,
P.
Cancer
Control Journal of the Moffitt Cancer Center 9(2), 2-8. 2002.
Adjuvant
therapy for breast cancer: Recommendations for management based on consensus
review and recent clinical trials.
Mincey,
B. A., Palmieri, F. M., and Perez, E. A.
Oncologist
7(3), 246-250. 2002.
Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early breast cancer: first results of
the ATAC randomised trial.
ATAC
Trialist Group
Lancet
359(9324), 2131-2139. 2002.
Aromatase
inhibitors for the endocrine adjuvant treatment of breast cancer.
Ravdin,
P.
Lancet 359(9324), 2126-2127. 2002.
Chemoprevention
of breast cancer - Implications for postmenopausal women.
Fabian,
C. J. and Kimler, B. F.
Drugs
& Aging 19(1), 43-78. 2002.
Sequential
power calculations in a recruitment phase of a multicentre trial - the
experience of the 'Arimidex (anastrozole), tamoxifen alone or in combination'
(ATAC) study.
Baum,
M., Cuzick, J., and ATAC Trialists' Group
Program/proceedings
- American Society of Clinical Oncology 21(1), 47A, Abs. 2002.
See the full ASCO author meeting abstract at
http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002324|00_29|00A|00_18|002002|00_19|00185,00.asp
Assessing
the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC
('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer (BC)
trial.
Fallowfield,
L. and Cella, D.
Program/proceedings
- American Society of Clinical Oncology 21(1), 40A, Abs. 2002.
See the full ASCO author meeting abstract at
http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002324|00_29|00A|00_18|002002|00_19|00159,00.asp
The
ATAC ('Arimidex', tamoxifen, alone or in combination) early breast cancer (EBC)
trial in postmenopausal (PM) patients: endometrial sub-protocol results.
Duffy,
S. R., Jackson, T. L., and ATAC Trialists' Group
Program/proceedings
- American Society of Clinical Oncology 21(1), 40A, Abs. 2002.
See the full ASCO author meeting abstract at
http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002324|00_29|00A|00_18|002002|00_19|00158,00.asp
Adjuvant
and neoadjuvant systemic therapy for breast cancer.
Schmid,
P. and Possinger, K.
Internist 43(3), 341-4, 347. 2002.
The
role of the new antiaromatase agents in the endocrine treatment of breast
cancer.
Huober,
J., Wagner, U., and Wallwiener, D.
Geburtshilfe
und Frauenheilkunde 62(1), 15-21. 2002.
Guidelines
on endocrine therapy of breast cancer EUSOMA.
Blamey,
R. W.
European Journal of Cancer 38(5), 615-616. 2002.
The
role of anti-aromatose agents in the treatment of breast cancer.
Wallwiener,
D., Wagner, U., and Huober, J.
Medizinische
Welt 53(1), 19, 20-19, 22. 2002.
Progress
in systemic therapy for breast cancer.
Piccart,
M. J., Cardoso, F., Atalay, G., and Biganzoli, L.
European Journal of Cancer 38(Suppl 3), S23-4, Abs.
2002.
Update
on new studies in Europe.
Cuzick,
J.
European Journal of Cancer 38(Suppl 3), S44, Abs.
2002.
Aromatase
inhibitors continue their ATAC on tamoxifen.
Nicholls,
H.
Trends in Molecular Medicine 8(4 Supplement), S12-S13.
2002.
Translating
basic cancer research into new cancer therapeutics.
Workman,
P. and Kaye, S. B.
Trends in Molecular Medicine 8(4 Supplement), S1-S9.
2002.
Tamoxifen
resistant and refractory breast cancer: value of aromatase inhibitors.
Goss,
P. E. and Strasser, K.
Drugs
62(6), 957-966. 2002.
Recent
advances in breast cancer (the Twenty-Fourth San Antonio Breast Cancer
Symposium, December, 2001).
Mokbel,
K. and Kirkpatrick, K. L.
Current
Medical Research and Opinion 18(1), 26-29. 2002.
The
ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer
trial in postmenopausal (PM) women.
Tobias,
J. S.
European Journal of Cancer 38(Suppl 3), S92, Abs.
2002.
ATAC
shows superiority of anastrozole monotherapy.
Carlson,
B.
Inpharma
(1325), 13-14. 2002.
Anastrozole
may be superior to tamoxifen as adjuvant treatment for postmenopausal patients
with breast cancer.
Fisher,
M. D. and O'Shaughnessy, J.
Clinical Breast Cancer 2 Pages, 269-271. 2002.
New
therapy approaches for breast cancer treatment.
Strahlentherapie und Onkologie 177(12), B1-B4. 2001.
Aromatase
inhibitors in adjuvant therapy.
Strahlentherapie und Onkologie 177(12), B4-B5. 2001.
The
ATAC (Arimidex, Tamoxifen, alone or in combination trial in post-menopausal
patients with operable breast cancer.
Tobias,
J.
European Journal of Cancer 37(Suppl 6), S171, Abs.
2001.
The
ATAC (Arimidex(TM), Tamoxifen, Alone or in Combination) adjuvant breast cancer
trial in postmenopausal (PM) patients (pts): Factors influencing the success of
PT recruitment.
Baum,
M.
European Journal of Cancer 37(Suppl 6), S172, Abs.
2001.
The
ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer
trial in postmenopausal (PM) women.
Baum,
M.
Breast Cancer Research and Treatment 69(3), 210, Abs.
2001.
The
ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial: The effectiveness of
transvaginal ultrasonography and hysteroscopy in the prediction of endometrial
abnormalities in asymptomatic menopausal women.
Jackson,
T. L. and Duffy, S. R. G.
Breast 10(Suppl 1), S30-S31. 2001.
The
ATAC (Arimidex, Tamoxifen, Alone in Combination) Trial: transvaginal ultrasound
scan findings overestimate observed pathological findings in postmenopausal
gynaecologically asymptomatic women before treatment.
Jackson,
T. L. and Duffy, S. R. G.
Breast 10(Suppl 1), S30. 2001.
The
ATAC (Arimidex, Tamoxifen, Alone or in Combination) breast cancer adjuvant
trial in postmenopausal women.
Baum,
M.
Breast 10(Suppl 1), S32. 2001.
Pharmacokinetics
of anastrozole and tamoxifen alone, and in combination, during adjuvant
endocrine therapy for early breast cancer in postmenopausal women: a
sub-protocol of the 'Arimidex(TM) and Tamoxifen Alone or in Combination' (ATAC)
trial.
Baum,
M., Dowsett, M., Coibion, M., Bianco, A. R., Cuzick, J., George, W. D., Gray,
J., Howell, A., Houghton, J., Williams, N., Sloane, J., Tobias, J., Buzdar, A.,
Anderson, M. D., Jackson, I., Sahmoud, T., Gallagher, J., Webster, A., Gangji,
D., Petrakova, K., Konopasek, B., Mares, P., Vodvarka, P., Alcazar, A., Campos,
O., Maxwell, A., Goedhals, Hacking, D., Landers, G., Smith, L., Vorobiof, D.
A., Werner, I. D., Blamey, R., Coleman, R., Grieve, R. J., Hickish, T.,
Nicholls, J. C., Nicholson, S., Raymond, S., Salman, A., Blum, J., Clark, R.,
Lyss, A., Miletello, G., Sternberg, J., Forbes, J., Nabholtz, J. M., Guastalla,
J. P., Distler, W., Klijn, J. G. M., Nagykalnai, T., Nicolucci, A., Constenla,
M., Nylen, U., Sainsbury, R., Mansel, R. E., Goerge, D., Buzdar, A. U., Locker,
G. Y., Pollard, S., Stroner, P., Buyse, M., Margolese, R., and Northover, J. M.
A.
British
Journal of Cancer 85(3), 317-324. 2001.
Pharmacokinetics
of 'Arimidex' and Tamoxifen Alone and in Combination in the ATAC Adjuvant
Breast Cancer Trial.
Dowsett,
M. and Study Group
Breast Cancer Research and Treatment 64(1), 64, Abs.
2000.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial: Transvaginal
ultrasound scan findings overestimate observed pathological findings in
postmenopausal gynaecologically asymptomatic women before treatment.
Jackson,
T. L., Duffy, S. R. G., and Study Group
Breast Cancer Research and Treatment 64(1), 64, Abs.
2000.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial: The effectiveness
of transvaginal ultrasonography and diagnostic hysteroscopy in the prediction
of endometrial abnormalities in asymptomatic postmenopausal women.
Jackson,
T. L., Duffy, S. R. G., and Study Group
Breast Cancer Research and Treatment 64(1), 63, Abs.
2000.
The
Anastrozole, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer
trial in post-menopausal women: Regional variations in surgical practice in
patients recruited into the trial: The ATAC Trialists' Group.
Sainsbury,
R.
Annals of Oncology 11(Suppl), 20, Abs. 2000.
The
Anastrozole, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer
trial in post-menopausal women: Regional variation in knowledge of hormone
receptor status prior to randomisation into the trial: The ATAC Trialists'
Group.
Howell,
A.
Annals of Oncology 11(Suppl), 20, Abs. 2000.
The
ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer
trial in post-menopausal women: Baseline endometrial sub-protocol data.
Jackson,
T. L., Duffy, S. R. G., and Study Group
European Journal of Cancer 36(Suppl), S69, Abs. 2000.
The
ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer
trial in post-menopausal women: Baseline patient and tumour characteristics.
Baum,
M.
European Journal of Cancer 36(Suppl), S69, Abs. 2000.
Managing
ATAC - The largest adjuvant breast cancer trial ever conducted.
Stroner,
P., Gallagher, J., Houghton, J., and Study Group
Controlled Clinical Trials 21(2 Supplement), 60S, Abs.
2000.
'Arimidex',
tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal
breast cancer.
Houghton,
J., Baum, M., and Study Group
European Journal of Cancer 34(Suppl), S83, Abs. 1998.
'Arimidex',
tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal
breast cancer.
Baum,
M., Houghton, J., and Study Group
European Journal of Cancer 34(Suppl), S39, Abs. 1998.